IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting
- None.
- None.
- New data on the completed dose-escalation of this Phase 1 trial highlights promising efficacy of INB-100 in patients with hematologic malignancies; updated data on durability of responses and long-term complete responses (CRs) to be presented.
- INB-100 continues to demonstrate a favorable safety profile with no dose-limiting toxicities (DLTs) and evidence of robust gamma-delta T cell expansion using recommended Phase 2 dose (RP2D).
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an abstract detailing new, positive data from the Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies has been selected for poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12, 2023.
Details for the ASH 2023 presentation are as follows:
Title: INB-100: A Pilot Study of Donor Derived, Ex-Vivo Expanded/Activated Gamma-Delta T Cell (EAGD) Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-Transplant Cyclophosphamide (PTCy)
Presenter: Joseph McGuirk, DO, The University of Kansas Cancer Center
Abstract #: 4853
Session Name: Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III
Date and Time: Monday, December 11, 2023, 6:00 PM - 8:00 PM PDT
Ten patients have been treated, completing the dose-escalation of this Phase 1 trial as of the abstract data cutoff of July 14, 2023. Updated data on safety and efficacy, including CRs and durability of response will be presented in December.
About the INB-100 Phase 1 Trial
The Phase 1 clinical trial (NCT03533816) is a dose-escalation trial of allogeneic derived, gamma-delta T cells from matched related donors that have been expanded and activated ex vivo and administered systemically to patients with hematologic malignancies following hematopoietic bone marrow transplantation (HSCT). The single-institution clinical trial is currently being conducted at The University of Kansas Cancer Center (KUCC). The primary endpoints of this trial are safety and tolerability, and secondary endpoints include rates of GvHD, relapse rate and overall survival.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.
IN8bio has initiated a Phase 2 trial of INB-400 in glioblastoma (GBM) at multiple centers across the United States and has two ongoing Phase 1 trials in solid and hematological tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other hematological and solid tumor cancers. For more information about IN8bio and its programs, please visit www.IN8bio.com.
Company Contact:
IN8bio, Inc.
Patrick McCall
+ 1 646.600.6GDT (6438)
info@IN8bio.com
Investors & Media:
Argot Partners
IN8bio@argotpartners.com
FAQ
What is the name of the company that announced the positive data?
What is the name of the therapy being tested in the Phase 1 trial?
What type of patients were included in the trial?
Where will the data be presented?
What is the session name for the presentation?
Who is the presenter of the data?
How many patients have been treated in the Phase 1 trial?
When will the updated data on safety and efficacy be presented?
